DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2008; 133(43): 2215-2228DOI: 10.1055/s-0028-1091265 CME-Beitrag | Review article Endokrinologie © Georg Thieme Verlag KG Stuttgart · New York Struma maligna – Schilddrüsenkarzinome Malignant goiter – Thyroid cancerChr Reiners1 , M. Dietlein2 , M. Luster3 1Klinik und Poliklinik für Nuklearmedizin, Universität Würzburg 2Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln 3Klinik und Poliklinik für Nuklearmedizin, Universität Ulm Recommend Article Abstract Buy Article Schlüsselwörter Schilddrüse - Struma - Karzinome - Diagnostik - Therapie - Nachsorge Keywords Thyroid - Goiter - Cancer - Diagnostics - Therapy - Follow-up Full Text References Literatur 1 Alexander C, Bader J B, Schaefer A, Finke C, Kirsch C M. Intermediate and long-term side-effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med. 1998; 39 1551-1554 2 Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Annals of Otology Rhinol Laryngol. 2006; 115 607-610 3 Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen W J, Tennvall J. Clinical radionuclide therapy dosimetry: the quest for the „Holy Gray”. Eur J Nucl Med Mol Imaging. 2007; 34 772-786 4 Carling T, Ocal I T, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer?. World J Surg. 2007; 31 916-923 5 Ceccarelli C, Canale D, Battisti P, Cagliaresi C, Moschini C, Fiore E, Grasso L, Pinchera A, Vitti P. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf). 2006; 65 446-452 6 Cooper D S, Specker B, Ho M, Sperling M, Ladenson P W, Ross D S, Ain K B, Bigos S T, Brierley J D, Haugen B R, Klein I, Robbins J, Sherman S I, Taylor T, Maxon 3rd H R. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998; 8 737-744 7 Cooper D S, Doherty G M, Haugen B R, Kloos R T, Lee S L, Mandel S J, Mazzaferri E L, McIver B, Sherman S I, Tuttle R M. The American Thyroid Association Guidelines Taskforce. . Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16 109-142 8 Cornett W S, Sharma A K, Day T A, Richardson M S, Hoda R S, van Heerden J A, Fernandes J K. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep. 2007; 9 152-158 9 Dietlein M, Schober O, Schicha H. Overtherapy or undertherapy for papillary thyroid microcarcinoma?. Nuklearmedizin. 2004; 43 107-114 10 Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, Luster M, Reiners C, Schicha H, Schober O. Deutsche Gesellschaft für Nuklearmedizin . Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin. 2007; 46 206-212 11 Dietlein M, Dressler J, Escher W, Grünwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O. Deutsche Gesellschaft für Nuklearmedizin . Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). [German]. Nuklearmedizin. 2007; 46 213-219 12 Dietlein M, Wieler H, Schmidt M, Schwab R, Goretzki P E, Schicha H. Routine measurement of serum calcitonin in patients with nodular thyroid disorders? [German]. Nuklearmedizin. 2008; 47 65-72 13 Dietlein M, Luster M, Reiners C. Differenziertes Schilddrüsenkarzinom: risikoadaptierte Behandlung und Nachsorge. Thieme-Refresher Onkologie. 2008 ; R1-R26 14 Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli J P, Caillou B, Ricard M, Lumbroso J D, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006; 91 2892-2899 15 Elaraj D M, Clark O H. Changing management in patients with papillary thyroid cancer. Curr Treat Options Oncol. 2007; 8 305-313 16 Farahati J, Demidchik E P, Biko J, Reiners C. Inverse association between age at the time of radiation exposure and extent of disease in cases of radiation-induced childhood thyroid carcinoma in Belarus. Cancer. 2000; 88 1470-1476 17 Farahati J, Geling M, Mäder U, Mörtl M, Luster M, Müller J G, Flentje M, Reiners C. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1984 – 1995. Thyroid. 2004; 14 141-147 18 Gao Z R, An R, Zhang Y X, Biersack H J. Targeted radionuclide therapy for patients with metastastic medullary thyroid carcinoma. Zhonghua Zhong Lio Zhi. 2006; 28 621-624 19 Gil Z, Patel S G. Surgery for thyroid cancer. Surg Oncol Clinc N Am. 2008; 17 93-120 20 Hegedüs L. Thyroid ultrasonography as a screening tool for thyroid diseases. Thyroid. 2004; 14 879-880 21 Hundahl S A, Fleming I D, Fremgen A M, Menck H R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985 – 1995. Cancer. 1998; 83 2638-2648 22 Ito Y, Miyauchi A. Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits and risks. World J Surg. 2007; 31 905-915 23 Jonklaas J. Role of radioactive iodine for adjuvant therapy and treatment of metastases. J Natl Compr Canc Netw. 2007; 5 631-640 24 Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hüfner M, Niederle B, Brabant G. German Society for Endocrinolgy (DGE) – Thyroid Section . Calcitonin measurements to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes. 2004; 112 52-58 25 Körber C, Geling M, Werner E, Mörtl M, Mäder U, Reiners C, Farahati J. Incidence of familial non-medullary thyroid carcinoma in the patient register of the Clinic and Policlinic of Nuclear Medicine, University of Würzburg. Nuklearmedizin. 2000; 29 27-32 26 Kumagai A, Reiners C, Drozd V, Yamashita S. Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management. Endocr J. 2007; 54 839-847 27 Krassas G E, Pontikides N. Male reproductive function in relation with thyroid alterations. Best Pract Res Clin Endocrinol Metab. 2004; 18 183-195 28 Lind P, Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 2006; 36 194-205 29 Luster M. Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncol. 2006; 45 1018-1030 30 Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007; 31 957-968 31 Mazzaferri E L. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007; 13 498-512 32 Miccoli P, Minuto M N, Ugolini C, Panicucci E, Berti P, Massi M, Basolo F. Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts. World J Surg. 2007; 31 888-894 33 Moley J F, Fialkowski E A. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg. 2007; 31 946-956 34 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J W, Wiersinga W European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154 787-803 35 Patel K N, Shaha A R. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006; 13 119-128 36 Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behaviour and outcome of papillary thyroid cancers smaller than 1.5 in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004; 89 3713-3720 37 Raue F, Frank-Raue K. Multiple endocrine neoplasia Type II: 2007 Update. Horm Research. 2007; Suppl5 101-104 38 Reiners C. Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?. Eur J Nucl Med Mol Imaging. 2003; 30 939-942 39 Reiners C, Demidchik Y E. Differentiated thyroid cancer in childhood: pathology, diagnosis, therapy. Pediatr Endocrinol Rev. 2003; 1 230-235 40 Reiners C. Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms, 2. Aufl. UNI-MED Science 2006 41 Ries L AG, Melbert D, Krapcho M, Stinchcomb D G, Howlader N, Horner M J, Mariotto A, Miller B A, Feuer E J, Altekruse S F, Lewis D R, Clegg L, Eisner M P, Reichman M, Edwards B K. SEER Cancer Statistics Review, 1975 – 2005. National Cancer Institute 42 Robert Koch Institut (RKI) .Krebs in Deutschland 2003 – 2004, Häufigkeiten und Trends. Saarbrücken, 6. überarbeitete Auflage. 2008 43 Sanders Jr E M, LiVolsi V A, Brierley J, Shin J, Randolph G W. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007; 31 934-945 44 Sawka A M, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein H C. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004; 89 3668-3676 45 Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga W M. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004; 150 105-112 46 Schlumberger M. Papillary and follicular thyroid carcinoma. Ann Endocrinol (Paris). 2007; 68 120-128 47 Schmid K W, Sheu S Y, Tötsch M, Görges R, Bockisch A, Mann K. Pathologie des Schilddrüsenkarzinoms. Der Onkologe. 2004; 11 29-39 48 Schmid K W. Problem areas of tumour classifications – thyroid carcinomas. Verh Dtsch Ges Pathol. 2007; 91 57-65 49 Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, Grünwald F, Müller-Gärtner H W, Schmutzler C, Köhrle J, Röher H D, Reiners C. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002; 29 775-782 50 Strasser J F, Raben A, Koprowski C. The role of radiation therapy in the management of thyroid cancer. Surg Oncol Clin N Am. 2008; 17 219-232 51 UICC (International Union Against Cancer) .Classification of malignant tumors, 5th edition. Hermanek P, Sobin LH (eds.) Berlin, Heidelberg, New York; Springer 1997 52 UICC (International Union Against Cancer) .Classification of malignant tumors, 6th edition. Sobin LH, Wittekind CH (eds.) New York; Wiley-Liss 2002 53 Weiss C L, Dralle H, Grimm O. Surgery of the thyroid gland I. Zentralbl Chir. 2004; 129 W76-83 54 Weiss C L, Dralle H, Grimm O. Surgery of the thyroid gland 2. Zentralbl Chir. 2004; 129 W98-99 55 World Health Organization .Pathology and Genetics of Head and Neck Tumours, Third Edition. De Dellis RA, Lloyd RV, Heitz PU, Eng C (eds.) Lyon; IARC Press 2004 Prof. Dr. Christoph Reiners Klinik und Poliklinik für Nuklearmedizin, Universität Würzburg Josef-Schneider-Str. 2 97080 Würzburg Phone: 0931/201-35868 Fax: 0931/201-35247 Email: reiners@nuklearmedizin.uni-wuerzburg.de
